The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price raised by The Goldman Sachs Group from $36.00 to $41.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other analysts have also recently weighed in on the company. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $44.63 on Friday. The company has a quick ratio of 6.99, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -11.71 and a beta of 1.00. The company has a fifty day simple moving average of $38.11 and a two-hundred day simple moving average of $32.60. Tarsus Pharmaceuticals has a 52 week low of $15.60 and a 52 week high of $52.99.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TARS. Swiss National Bank lifted its stake in shares of Tarsus Pharmaceuticals by 1.4% in the first quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after buying an additional 600 shares during the period. Alpha DNA Investment Management LLC increased its position in shares of Tarsus Pharmaceuticals by 9.1% during the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock worth $412,000 after purchasing an additional 1,261 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares during the period. Profund Advisors LLC lifted its position in shares of Tarsus Pharmaceuticals by 26.8% in the second quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock valued at $248,000 after buying an additional 1,929 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $61,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.